PTCT PTC Therapeutics Inc.

45.14
-1.17  -3%
Previous Close 46.31
Open 46.36
Price To Book 8.47
Market Cap 2266695756
Shares 50,214,793
Volume 1,820,152
Short Ratio 4.26
Av. Daily Volume 890,047

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial has commenced - noted October 12, 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. Expects to initiate new trial by the end of 2018.
Ataluren
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review extended to October 6, 2018.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis
Noted March 15, 2018 that trial has transitioned into pivotal phase. Updated positive Phase 1 data released June 16, 2018.
RG7916 - FIREFISH
Spinal Muscular Atrophy (SMA) Type 1

Latest News

  1. How’s PTC Therapeutics Positioned in September?
  2. Analyzing PTC Therapeutics’ Performance in September
  3. How Financially Strong Is PTC Therapeutics Inc (NASDAQ:PTCT)?
  4. PTC Therapeutics to Participate at Upcoming Investor Conference
  5. PTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day
  6. Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics
  7. New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix — Consolidated Revenues, Company Growth, and Expectations for 2018
  8. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  9. PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics
  10. Today's Research Reports on Trending Tickers: Spark Therapeutics and PTC Therapeutics
  11. Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript
  12. PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
  13. PTC Therapeutics: 2Q Earnings Snapshot
  14. PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update
  15. PTC Therapeutics, Inc. to Host Earnings Call
  16. Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
  17. PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results
  18. Biogen Stock Trending Higher on Strong Q2 2018 Results
  19. A Look at PTC Therapeutics’ Financial Position

SEC Filings

  1. D - Notice of Exempt Offering of Securities 181055193
  2. 8-K - Current report 181040118
  3. CT ORDER - Confidential treatment order 181038751
  4. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181035861
  5. 8-K - Current report 181035842
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998729
  7. 8-K - Current report 18997977
  8. 8-K - Current report 18986750
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 18974852
  10. 8-K - Current report 18960758